Portfolio News
Sofinnova Capital
Avantium reaches key commercial milestone for its FDCA flagship plant with commitments for >50% of its output
Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This brings the total of such offtake contracts to five.
Related Strategy
Industrial BiotechRelated Company
AvantiumAMSTERDAM, 7 April 2021, 18:00 hrs CEST – Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This brings the total of such offtake contracts to five.
The planned FDCA flagship plant is set to produce 5 kilotonnes of FDCA (furandicarboxylic acid) per annum, the key building block for the 100% fossil-free, recyclable polymer PEF (polyethylene furanoate). Including an additional commitment from one of the previously announced offtake partners, the five conditional offtake agreements represent a total offtake volume of over 50% of the FDCA production capacity from the flagship plant. This marks an important step towards a positive Final Investment Decision (FID) for the construction of the world’s first commercial FDCA plant, which Avantium would plan to open in 2023.
Related News
RefleXion expands access to SCINTIX therapy with first freestanding cancer center
BrightHeart unveils breakthrough AI results at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, revolutionizing prenatal care
Mainstay Medical announces positive outcomes from landmark RESTORE clinical trial of ReActiv8®
Bioptimus hits $76M funding milestone and prepares to launch groundbreaking foundation model for biology
Mediar Therapeutics enters into global licensing agreement with Lilly to advance first-in-class WISP1 antibody for the treatment of idiopathic pulmonary fibrosis (IPF)